CD4 and neoplasm: The results from xCell and CIBERSORT consistently indicated that killer cells such as memory CD4 T cells and central memory CD8 T cells, which play critical roles in anti-tumor immunity and immunotherapy, were significantly richer in the PI3K pathway mutation group.